During the last session, Puma Biotechnology Inc (NASDAQ:PBYI)’s traded shares were 0.54 million, with the beta value of the company hitting 1.03. At the end of the trading day, the stock’s price was $3.00, reflecting an intraday gain of 3.45% or $0.1. The 52-week high for the PBYI share is $7.73, that puts it down -157.67 from that peak though still a striking 26.0% gain since the share price plummeted to a 52-week low of $2.22. The company’s market capitalization is $147.26M, and the average intraday trading volume over the past 10 days was 0.84 million shares, and the average trade volume was 368.50K shares over the past three months.
Puma Biotechnology Inc (PBYI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. PBYI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.14.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Puma Biotechnology Inc (NASDAQ:PBYI) trade information
Puma Biotechnology Inc (PBYI) registered a 3.45% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.45% in intraday trading to $3.00, hitting a weekly high. The stock’s 5-day price performance is 23.97%, and it has moved by 7.14% in 30 days. Based on these gigs, the overall price performance for the year is -27.54%. The short interest in Puma Biotechnology Inc (NASDAQ:PBYI) is 3.19 million shares and it means that shorts have 14.34 day(s) to cover.
Puma Biotechnology Inc (PBYI) estimates and forecasts
Statistics show that Puma Biotechnology Inc has underperformed its competitors in share price, compared to the industry in which it operates. Puma Biotechnology Inc (PBYI) shares have gone down -25.00% during the last six months, with a year-to-date growth rate less than the industry average at -29.85% against 17.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -54.84% this quarter and then jump 220.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -4.97% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 52.5M as predicted by 2 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 47.5M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 72.2M and 43.77M respectively. In this case, analysts expect current quarter sales to shrink by -27.29% and then jump by 8.53% in the coming quarter.
While earnings are projected to return -33.33% in 2024.
PBYI Dividends
Puma Biotechnology Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Puma Biotechnology Inc (NASDAQ:PBYI)’s Major holders
Puma Biotechnology Inc insiders own 15.14% of total outstanding shares while institutional holders control 67.78%, with the float percentage being 79.88%. VANGUARD GROUP INC is the largest shareholder of the company, while 138.0 institutions own stock in it. As of 2024-06-30, the company held over 3.6 million shares (or 7.4684% of all shares), a total value of $11.73 million in shares.
The next largest institutional holding, with 3.57 million shares, is of BLACKROCK INC.’s that is approximately 7.4141% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $11.65 million.
Also, the Mutual Funds coming in first place with the largest holdings of Puma Biotechnology Inc (PBYI) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.27 shares. This amounts to just over 2.59 percent of the company’s overall shares, with a $3.81 million market value. The same data shows that the other fund manager holds slightly less at 1.09, or about 2.23% of the stock, which is worth about $3.28 million.
